Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 10, 2008, Pages 1831-1837

  Chan, Dick C ^a   Watts, Gerald F ^a   Ooi, Esther M M ^a   Ji, Juying ^a   Johnson, Anthony G ^b   Barrett, P Hugh R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cardiovascular disease; Fenofibrate; Insulin resistance; Lipoprotein metabolism; Obesity; Statin

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B48; APOLIPOPROTEIN C3; ATORVASTATIN; FENOFIBRATE; LEUCINE; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DOWN REGULATION; KINETICS; MASS FRAGMENTOGRAPHY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS A; APOLIPOPROTEINS B; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DOWN-REGULATION; DYSLIPIDEMIAS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINETICS; LIPOPROTEINS, VLDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, BIOLOGICAL; PROCETOFEN; PYRROLES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 53449092689     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.170530     Document Type: Article

References (37)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1998; 37:1595-1607.
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
3. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733-749.
4. Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, Taskinen MR. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2005;25:1697-1703.
5. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism. 2002;51:1041-1046.
6. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 2001;12:297-304.
7. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985;75:384-390.
8. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266:18259-18267.
9. Cohn JS, Tremblay M, Batal R, Jacques H, Rodriguez C, Sterner G, Mamer O, Davignon J. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis. 2004;177: 137-145.
10. Nguyen MN, Chan DC, Dwyer KP, Bolitho P, Watts GF, Barrett PHR. Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma. J Lipid Res. 2006;47: 1274-1280.
11. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest. 2004;114:1493-1503.
12. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Pros Harm Res. 2001;56:239-263.
13. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998;98:2513-2519.
14. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation. 1998;97:1436-1439.
15. Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol. 1999;10:561-574.
16. Diabetes Atherosclerosis Intervention Study (DAIS) Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes. Lancet. 2001;357:905-910.
17. Ginsberg HN. Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia. J Clin Endocrinol Metab. 2006;91: 383-392.
18. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
19. Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation. 1987;76:504-507.
20. Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fievet C, Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 1999;452:160-164.
21. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003; 52:803-811.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-2497.
23. Huff MW, Fidge NH, Nestel PJ, Billington T, Watson B. Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J Lipid Res. 1981;22:1235-1246.
24. Chan DC, Nguyen MN, Watts GF, Barrett PHR. Plasma apolipoprotein C-III transport in central obese men: associations with very-low density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J Clin Endocrinol Metab. 2008;93:557-564.
25. Chan DC, Watts GF, Barrett PHR, Mori TA, Beilin LJ, Redgrave TG. Mechanism of action of an HMG CoA reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. J Clin Endocrinol Metab. 2002;87:2283-2289.
26. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res. 2004;45:174-185.
27. Bach-Ngohou K, Ouguerram K, Frenais R, Maugère P, Ripolles-Piquer B, Zaïr Y, Krempf M, Bard JM. Influence of atorvastatin on apolipoprotein e and AI kinetics in patients with type 2 diabetes. J Pharmacol Exp Ther. 2005;315:363-369.
28. Chan DC, Watts GF, Nguyen MN, Barrett PHR. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr. 2006;84:37-43.
29. Ooi TC, Heinonen T, Alaupovic P, Davignon J, Leiter L, Lupien PJ, Sniderman AD, Tan MH, Tremblay G, Sorisky A, Shurzinske L, Black DM. Efficacy and safety of a new hydroxymethylglutaryl-Coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 1997; 17:1793-1799.
30. Dallinga-Thie GM, Berk-Planken HL, Bootsma AH, Jansen H. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: A potential mechanism to lower plasma triglycerides. Diabetes Care. 2004;27: 1358-1364.
31. Chan DC, Watts GF, Mori TA, Barrett PHR, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest. 2002;32:429-436.
32. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest. 2001;107:1423-1432.
33. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bendadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. Effects of the PPARy aginist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2006;115:1323-1332.
34. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997; 38:2173-2192.
35. van Dijk KW, Rensen PCN, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr Opin Lipidol. 2004;15:239-246.
36. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation. 2000;102:1886-1892.
37. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 2003;23:853-858.